Washington (ChatterShmatter) – Arena Pharmaceuticals announced the results of a trial on their obesity drug Lorcaserin, showing that it does work, but not very effectively.
Arena has been working to get this new drug approved for quite some time by the U.S. Food and Drug Administration (FDA), but has seemingly just missed the mark.
The idea behind the trial that was carried out was to see if patients could lose more weight on the drug than if they were taking a placebo.
The FDA requires that there is a 5% increase in weight loss when the drug is compared to the placebo, but this mark was not reached.
On average, after a year went by, patients lost 8.2% of their body weight or about 17.9 pounds on the drug, compared to 3.4% of their body weight or 7.3 pounds on the placebo, missing the 5% mark.
This disappointing result sent shares of the company down 34%.